Nyxoah raises €25m private financing from ResMed and existing shareholders

– BELGIUM, Mont-Saint-Guibert –  Nyxoah S.A., a healthtech company developing neuromodulation-based therapeutic solutions for sleep-disordered breathing conditions, today announced that it has raised €25 million in a private financing round.

ResMed Inc., a world-leading digital health company in the fields of sleep apnea, COPD, and other chronic diseases, joined as a new shareholder.

Under the lead of Robert Taub, Nyxoah executive chairman, Cochlear Limited and several historical shareholders completed the €25 million financing round.

The proceeds will enable Nyxoah to further advance in developing long-term clinical evidence on the Genio system, prepare for the IDE pivotal trial in the United States and accelerate the ongoing market access and commercialization activities in Europe, Australia and New Zealand.

Olivier Taelman, CEO of Nyxoah, commented: “We have an innovative approach to treating OSA. Having ResMed, the global leader in sleep apnea, support this significant funding round along with our existing shareholders will help Nyxoah to further accelerate its development.”

About Obstructive Sleep Apnea and the Genio system

OSA is the world’s most common sleep disorder, affecting almost one billion people globally1.

OSA makes a person stop breathing during sleep, while the airway repeatedly becomes partially or totally blocked, limiting the amount of air that reaches the lungs. OSA is a chronic condition that is associated with increased mortality risk and comorbidities, including cardiovascular diseases, type 2 diabetes, obesity, depression and stroke. The current standard of care consists of Positive Airway Pressure therapy, a treatment whereby air is pushed into the upper airway to keep it open.

The Genio system is the world’s first and only, battery-free, leadless and minimally invasive implanted neurostimulator designed to keep the upper airway open during sleep for certain people with OSA by bilateral stimulation of the hypoglossal nerve.

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep-disordered breathing conditions. Nyxoah’s lead solution platform is based on the Genio system, a validated, user-centered, next-generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep-disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio system. The IDE pivotal study to prepare for US market entrance is currently in discussion with the FDA.

For more information: http://www.nyxoah.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.